ESMO 24: Summit/Akeso Broaden Base Of Solid Tumor Indications For Anti-PD-1xVEGF Bispecific

Phase II data at the ESMO meeting showed promising efficacy for the drug beyond NSCLC, particularly in certain indications of colorectal and head-and-neck cancers.